Hendrik Schulze‐Koops

17.0k total citations · 2 hit papers
285 papers, 9.2k citations indexed

About

Hendrik Schulze‐Koops is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Hendrik Schulze‐Koops has authored 285 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 144 papers in Rheumatology, 104 papers in Immunology and 53 papers in Hematology. Recurrent topics in Hendrik Schulze‐Koops's work include Rheumatoid Arthritis Research and Therapies (86 papers), Autoimmune and Inflammatory Disorders Research (51 papers) and T-cell and B-cell Immunology (43 papers). Hendrik Schulze‐Koops is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (86 papers), Autoimmune and Inflammatory Disorders Research (51 papers) and T-cell and B-cell Immunology (43 papers). Hendrik Schulze‐Koops collaborates with scholars based in Germany, United States and United Kingdom. Hendrik Schulze‐Koops's co-authors include Alla Skapenko, Peter E. Lipsky, Joachim R. Kalden, Jan Leipe, Martin Aringer, Laurie S. Davis, John J. Cush, Andrew P. Cope, Georg Schett and Claudia Dechant and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

Hendrik Schulze‐Koops

270 papers receiving 9.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trial of Tocilizumab in Giant-Cell Arteritis

2017 815 citations Georg Schett, Hendrik Schulze‐Koops et al. profile →
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

2012 790 citations Hendrik Schulze‐Koops, Carol A. Connell et al. profile →

Peers

Countries citing papers authored by Hendrik Schulze‐Koops

Since Specialization

Citations

This map shows the geographic impact of Hendrik Schulze‐Koops's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hendrik Schulze‐Koops with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hendrik Schulze‐Koops more than expected).

Fields of papers citing papers by Hendrik Schulze‐Koops

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hendrik Schulze‐Koops. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hendrik Schulze‐Koops. The network helps show where Hendrik Schulze‐Koops may publish in the future.

Co-authorship network of co-authors of Hendrik Schulze‐Koops

This figure shows the co-authorship network connecting the top 25 collaborators of Hendrik Schulze‐Koops. A scholar is included among the top collaborators of Hendrik Schulze‐Koops based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hendrik Schulze‐Koops. Hendrik Schulze‐Koops is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sonographic study on vessel wall remodelling of the cranial and axillary arteries in giant cell arteritis under treatment: implications for diagnosis of relapses and impact of tocilizumab treatment 2025 ·Clinical and Experimental Rheumatology ·(unknown), (unknown), (unknown), Christian Lottspeich, (unknown), (unknown), Hendrik Schulze‐Koops, Michael Czihal	1
2	A Clinical Probability-Based, Stepwise Algorithm for the Diagnosis of Giant Cell Arteritis: Study Protocol and Baseline Characteristics of the First 50 Patients Included in the Prospective Validation Study with Focus on Cranial Symptoms 2025 ·Journal of Clinical Medicine ·(unknown), (unknown), (unknown), Christian Lottspeich, Anja Löw, (unknown), Sandra E. Hasmann, (unknown), (unknown), (unknown), (unknown), (unknown), Marc J. Mackert, Siegfried Priglinger, Heiko Schulz, Doris Mayr, (unknown), (unknown), Hendrik Schulze‐Koops, Michael Czihal	0
3	Clinical features, course, and risk factors of infection-associated secondary hemophagocytic lymphohistiocytosis 2025 ·Infection ·(unknown), (unknown), Hans‐Joachim Stemmler, Stephanie-Susanne Stecher, Hendrik Schulze‐Koops, Fabian Hauck, (unknown), (unknown), Karsten Spiekermann	0
4	A rare side effect of methotrexate therapy: drug-induced osteopathy with multiple fractures of the lower limb 2023 ·RMD Open ·(unknown), Nina Hesse, Alla Skapenko, Hendrik Schulze‐Koops	4
5	A patient with Takayasu arteritis presenting with malignant hypertension: a case report 2023 ·European Heart Journal - Case Reports ·Laura Sierra, Leonhard Binzenhöfer, Hendrik Schulze‐Koops, Korbinian Lackermair, Steffen Maßberg, Enzo Lüsebrink	1
6	sCD25 as an independent adverse prognostic factor in adult patients with HLH: results of a multicenter retrospective study 2022 ·Blood Advances ·(unknown), (unknown), Hans‐Joachim Stemmler, Fabian Hauck, Hendrik Schulze‐Koops, Stephanie-Susanne Stecher, Michael Starck, Clemens‐Martin Wendtner, Peter Bojko, Marcus Hentrich, (unknown), Katharina S. Götze, Florian Bassermann, Michael von Bergwelt‐Baildon, Karsten Spiekermann	11
7	Reactive arthritis after SARS-CoV-2 infection 2022 ·RMD Open ·(unknown), Alla Skapenko, Hendrik Schulze‐Koops	5
8	Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial 2022 ·Annals of the Rheumatic Diseases ·Andra Bălănescu, Gustavo Citera, Virginia Pascual‐Ramos, Deepak L. Bhatt, Carol A. Connell, David Gold, (unknown), (unknown), Andrea Shapiro, Janet Pope, Hendrik Schulze‐Koops	43
9	Digital Health Transition in Rheumatology: A Qualitative Study 2021 ·International Journal of Environmental Research and Public Health ·(unknown), (unknown), Martin Krusche, Johanna Mücke, Robert Prill, Martin Heinze, Martin Welcker, Hendrik Schulze‐Koops, Nicolas Vuillerme, Georg Schett, Johannes Knitza	36
10	Methotrexate does not increase the risk of liver fibrosis in patients with rheumatoid arthritis: assessment by ultrasound elastography (ARFI-MetRA study) 2021 ·Rheumatology International ·Martin Feuchtenberger, (unknown), Axel Nigg, Hendrik Schulze‐Koops, Arne Schäfer	8
11	Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines 2021 ·RMD Open ·Hendrik Schulze‐Koops, Christof Specker, Alla Skapenko	11
12	Hyperechogenic intimal lesions and wall thickness of the temporal and facial arteries in elderly patients with arterial occlusions of the eye 2021 ·RMD Open ·Michael Czihal, Anton Köhler, (unknown), Ulrich Hoffmann, Hendrik Schulze‐Koops, Claudia Dechant, (unknown), Marc J. Mackert, Christian Lottspeich	3
13	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2 2020 ·Annals of the Rheumatic Diseases ·Robert Landewé, Pedro Machado, Féline P B Kroon, Hans Bijlsma, Gerd R Burmester, Loreto Carmona, Bernard Combe, Massimo Galli, Laure Gossec, Annamaria Iagnocco, John D. Isaacs, Xavier Mariette, Iain B. McInnes, Ulf Müeller-Ladner, Peter Openshaw, Josef S Smolen, Tanja Stamm, Dieter Wiek, Hendrik Schulze‐Koops	153
14	Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial 2020 ·Annals of the Rheumatic Diseases ·Claudia Kedor, Joachim Listing, Jan Zernicke, Anja Weiß, Frank Behrens, Norbert Blank, Jörg Henes, Joern Kekow, Andrea Rubbert‐Roth, Hendrik Schulze‐Koops, Eva Seipelt, Christof Specker, Eugen Feist	64
15	Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52 2020 ·Annals of the Rheumatic Diseases ·Josef S Smolen, Philip J. Mease, Hasan Tahir, Hendrik Schulze‐Koops, Inmaculada de la Torre, Lingnan Li, Maja Hojnik, Christophe Sapin, Masato Okada, Roberto Caporali, Jordi Gratacós, Philippe Goupille, Soyi Liu Leage, Sreekumar Pillai, Peter Nash	58
16	[Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)]. 2016 ·PubMed ·Uta Kiltz, Rieke Alten, Marcelo P. Fleck, K. Krüger, Bernhard Manger, Ulf Müller‐Ladner, H. Nüßlein, (unknown), Andreas Schwarting, Hendrik Schulze‐Koops, Anne‐Kathrin Tausche, Joseph M. Braun	17
17	Anti-Interleukin 17A Monoclonal Antibody Secukinumab Reduces Signs and Symptoms of Psoriatic Arthritis in a 24-Week Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial 2011 ·Data Archiving and Networked Services (DANS) ·Iain B. McInnes, (unknown), (unknown), (unknown), (unknown), John D. Isaacs, (unknown), (unknown), Hendrik Schulze‐Koops, Sandro Gsteiger, A. Bertolino, Wolfgang Hueber, (unknown)	2
18	Th17 cells expressing KIR3DL2 + and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis: Commentary 2011 ·T. Huizinga, Peter A. Nigrović, Eric Ruderman, Hendrik Schulze‐Koops	2
19	Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation: Commentary 2011 ·T. Huizinga, Peter A. Nigrović, Eric Ruderman, Hendrik Schulze‐Koops	1
20	Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS): Commentary 2011 ·T. Huizinga, Peter A. Nigrović, Eric Ruderman, Hendrik Schulze‐Koops	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact